Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain.
- Published in:
- Oncology & Therapy, 2025, v. 13, n. 2, p. 381, doi. 10.1007/s40487-025-00333-7
- By:
- Publication type:
- Article